查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1425116

全球診斷酶市場：預測（2024-2029）

Diagnostic Enzymes Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年全球診斷酵素市場規模為46.46億美元。

使用酵素來識別和分析生物異常的概念是基於內源性酵素的活性對健康敏感的事實。此外，基材濃度的波動也是生理異常的徵兆，可以透過酵素來檢測。例如，使用膽固醇氧化酶測量膽固醇可以識別可能的心血管問題或高血壓。在生物技術中，酵素有時被用來開發分析和檢測技術，例如酵素結合免疫吸附檢測法(ELISA) 和偶聯多酶反應測定。

老年人口增加

由於人口老化，診斷酶市場預計將成長得更快。據世界衛生組織 (WHO) 稱，到 2030 年，六分之一的人口將超過 60 歲，其中新興國家是罪魁禍首。 2020年至2050年間，80歲及以上的人口數量預計將增加兩倍，達到4.26億。老年人通常患有聽力損失、白內障、屈光不正、背部和頸部疼痛、骨關節炎、糖尿病、憂鬱症和失智症，這些都導致​​學名藥的使用增加。隨著年齡的成長，我們變得更容易同時感染多種疾病，這可能會刺激診斷酵素市場的成長。

用於糖尿病診斷的診斷酶

辨識糖尿病最快、最簡單的方法是血糖值測試。參與葡萄糖代謝的酵素與葡萄糖反應，從而檢測血液樣本中葡萄糖的存在。 Creative Enzymes 提供不同供應商的各種與糖尿病相關的酵素。例如，葡萄糖-6-磷酸去氫酶的缺乏與糖尿病的風險增加有關。葡萄糖氧化酵素和葡萄糖去氫酵素最常用於臨床血糖檢測。為了開始使用葡萄糖，己糖激酶催化葡萄糖磷酸化產生葡萄糖 6-磷酸。

用於肝功能測試的診斷酶

肝功能障礙的治療和肝病的早期發現取決於肝功能檢查的結果。人們已經創建了各種酶促反應來識別與各種肝損傷相關的奇怪化合物的存在，從而推動了診斷酶行業的發展。例如，Creative Enzymes 是一種診斷酶產品，支持肝功能評估的臨床和科學應用。該業務包括多種天然來源或生化合成的肝功能相關酶，以滿足消費者的特殊需求。蘋果酸去氫酶、D-乳酸去氫酶、乙醇去氫酶和鹼性磷酸酶均可以天然或重組形式取得。

對核酸酶的需求不斷增加

核酸酶將 DNA 和 RNA 的核苷酸鏈分解成更小的片段。 DNA 分子被核酸酶分解，核酸酶也會分解連接 DNA 鏈中核苷酸的磷酸二酯鍵。核酸外切酶和核酸內切酶是兩種不同類型的核酸酶。此外，酵素專家 Biocatalysts Ltd 於 2023 年 3 月推出了 Nuclease 46L (N046L)，這是一種用於分解多種來源的多種核酸的新型酵素。這種酶主要是作為一種低成本方法而開發的，用於在各種生物技術應用中去除 DNA。這些發展對於診斷酵素產業的進步至關重要。

在北美，診斷酶市場預計將穩定成長。

由於對酶的需求不斷成長以及感染疾病的流行，預計北美將佔據主導地位。例如，FDA 已授權實驗室開發的 COVID-19 診斷方法緊急使用，以應對持續的感染疾病爆發。為了檢測 SARS-CoV-2，大多數緊急使用授權也採用基於 RT-PCR 的測試和酵素結合免疫吸附測試。由於 RT-PCR 使用多種酶，因此此類檢測方法的開發預計將在北美診斷酶市場上獲利。

政府關於診斷酶的舉措

  • 根據國家衛生使命，各州和首府將按照計劃實施計劃（PIP）和總體資源框架中規定的要求，在公共衛生設施中免費提供基本藥物，並獲得財政援助。為了確保普遍獲得基本藥物，衛生部提案在公共機構中提供特定設施的基本藥物清單（EDL）。
  • 快速診斷測試（RDT）在快速且準確地識別傳染性微生物並確定其對各種抗生素的敏感性方面具有巨大潛力。因此，預計它將在未來的抗菌藥物管理（AMS）計劃中發揮重要作用。在某些特定情況下部署 AMS 的國際標準已鼓勵使用 RDT。

診斷酵素產品

  • EKF Diagnostics：診斷酵素由 EKF Life Sciences 生產並用作臨床診斷劑。這些包括水楊酸羥化酶、BETA-羥基丁酸去氫酶和芳基醯胺酶。這些診斷酶以“Stand Biochemistry”品牌在市場上銷售，用於臨床診斷試劑製造商和OEM試劑的試劑生產。
  • 旭化成製藥：為了預防糖尿病併發症，正確控制血糖值很重要。糖化白蛋白測量採血前 2 週的平均血糖值。糖化白蛋白使用2004年推出的LucicaTM GA-L液體試劑檢測套組進行測量。糖化白蛋白於2009年被日本紅十字會採納為捐血的檢測項目。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 先決條件

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章診斷酵素市場：依類型

  • 介紹
  • Taq聚合酵素
  • MMLV RT
  • HIV RT
  • NG
  • 核糖核酸酶抑制劑
  • 其他

第6章診斷酵素市場：依產品類型

  • 介紹
  • 分子酵素
  • 臨床酵素

第7章診斷酵素市場：依應用分類

  • 介紹
  • 糖尿病
  • 腫瘤學
  • 心臟病學
  • 感染疾病
  • 其他

第8章診斷酵素市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 併購/協議/合作
  • 供應商競爭力矩陣

第10章 公司簡介

  • EKF Diagnostics
  • Sekisui Diagnostics
  • Negen Corporation
  • Novozymes
  • CustomBiotech
  • TOYOBO
  • Asahi Kasei
  • Sekisui Medical Co. Ltd.
  • NZYTech
  • Megazyme
簡介目錄
Product Code: KSI061616211

The diagnostic enzymes market was valued at US$4.646 billion in 2022.

The notion of employing enzymes to identify and analyze biological abnormalities is based on the fact that the activity of endogenous enzymes is sensitive to health. In addition, variations in the concentration of the substrate, which are also a sign of physiological abnormalities, can be detected by enzymes. For instance, measuring cholesterol using cholesterol oxidase might identify probable cardiovascular problems or high blood pressure. In biotechnologies, enzymes may be employed to create analysis and detection techniques like the enzyme-linked immunosorbent assay (ELISA) and coupled multi-enzyme reaction assays.

Increase in geriatric population

The diagnostic enzymes market is expected to expand more quickly as a result of the aging population. By 2030, 1 in 6 individuals will be 60 or older, with emerging countries being primarily responsible for this growth, according to the World Health Organisation. Between 2020 and 2050, the number of persons 80 or older is projected to treble, reaching 426 million. Elderly patients typically have hearing loss, cataracts and refractive errors, back and neck pain and osteoarthritis, diabetes, depression, and dementia, which contributes to the rising usage of generic medications. People are more prone to several diseases at once as they get older which can fuel the growth of the diagnostic enzymes market.

Diagnostic Enzymes for Diabetes Diagnosis

The quickest and easiest way to identify diabetes is with a blood sugar test. Enzymes involved in the metabolism of glucose are created to react with glucose and, as a result, to detect the presence of glucose in blood samples. Creative Enzymes carries a wide range of diabetes-related enzymes from various suppliers. For instance, a lack of glucose-6-phosphate dehydrogenase has been linked to an increased risk of developing diabetes. For clinical blood sugar tests, glucose oxidase and glucose dehydrogenase are most frequently utilized. To start using glucose, hexokinase catalyzes the phosphorylation of glucose to produce glucose 6-phosphate.

Diagnostic enzymes for liver function test

The therapy of individuals with hepatic dysfunction and early detection of liver illnesses depend on the results of liver function tests. To identify the presence of odd compounds linked to various forms of liver injury or disorders, a variety of enzymatic reactions are created which boosts the diagnostic enzymes industry. For instance, with their diagnostic enzyme products, Creative Enzymes has supported the clinical and scientific usage of liver function assessment. The business includes several liver function-related enzymes from various natural sources or biochemical syntheses to satisfy the unique requirements of the consumer. Malate dehydrogenase, D-lactate dehydrogenase, alcohol dehydrogenase, and alkaline phosphatase are all available in either natural or recombinant forms.

Rising demand for nuclease enzymes

An enzyme called nuclease divides the DNA and RNA nucleotide chain into smaller pieces. The DNA molecule is broken down by the nuclease enzyme, as well as the phosphodiester bonds connecting one nucleotide to another in the DNA strand. Exonucleases and endonucleases are the two distinct kinds of nucleases. Additionally, in March 2023, Nuclease 46L (N046L), a novel enzyme from enzyme experts Biocatalysts Ltd, is now available for the breakdown of various nucleic acids from a variety of sources. It was created primarily as a low-cost method to get rid of DNA in a variety of biotechnology applications. These developments are essential for the development of the diagnostic enzymes industry.

In North America, it is projected that the diagnostic enzymes market will grow steadily.

North American region is expected to take a leading position as a result of the expanding demand for enzymes and the prevalence of infectious illnesses there. For instance, the FDA has authorized COVID-19 laboratory-developed diagnostics for use in emergencies to tackle the ongoing outbreak. For the detection of SARS-CoV-2, the majority of these emergency usage authorizations also employ RT-PCR-based testing and enzyme-linked immunosorbent tests. Because RT-PCR uses a lot of enzymes, the development of such assays is projected to be profitable in the North American diagnostic enzymes market.

Government initiatives for diagnostic enzymes

  • Following the National Health Mission, States and UTs get financial assistance to offer free basic medications in public health facilities following the demands stated in their Programme Implementation Plans (PIPs) and the overall resource envelope. To guarantee universal access to necessary medications, the ministry has proposed that a facility-specific Essential Drugs List (EDL) be made accessible at public healthcare institutions.
  • Rapid diagnostic tests (RDTs) have a great deal of potential for quickly and accurately identifying infectious organisms and determining their susceptibility to various types of antibiotics. As a result, they are expected to play a bigger role in antimicrobial stewardship (AMS) programs in the future. RDT usage is already encouraged by international standards for the deployment of AMS in a few particular contexts.

Diagnostic enzymes Products

  • EKF Diagnostics, Diagnostic enzymes are produced by EKF Life Sciences and utilised as clinical diagnostic reagents. Among these are salicylate hydroxylase, beta-hydroxybutyrate dehydrogenase, and arylacylamidase. These diagnostic enzymes are sold commercially for use in the manufacturing of third-party clinical diagnostic firms' reagents as well as OEM reagents under the Stanbio Chemistry brand.
  • Asahi Kasei Pharma, Controlling blood sugar properly is crucial for avoiding diabetic complications. The glycated albumin measures the average glycemia throughout the two weeks before the blood sample. Glycated albumin is measured using the LucicaTM GA-L liquid reagent test kit, which was introduced in 2004. Glycated albumin was included as a laboratory test component for donated blood by the Japan Red Cross in 2009.

Market Key Developments

  • In June 2023, scientists from the Indian Institute of Science created a fluorogenic probe to identify an enzyme associated with the early stages of the neurodegenerative illness Alzheimer's.
  • In February 2023, a pioneer in the production and delivery of diagnostic enzymes, Creative Enzymes, and research diagnostics. The company recently included pancreatic and kidney enzymes.
  • In December 2022, Ginkgo Enzyme Services was launched, according to Ginkgo Bioworks, which is developing the top platform for cell programming and biosecurity. Ginkgo Enzyme Services is supported by optimized, patented bacterial and fungal host strains, machine learning-guided protein design, and ultra-high throughput screening.

Segmentation:

By Type

  • Taq Polymerase
  • MMLV RT
  • HIV RT
  • UNG
  • RNase Inhibitors
  • Others

By Product Type

  • Molecular Enzymes
  • Clinical Enzymes

By Application

  • Diabetes
  • Oncology
  • Cardiology
  • Infectious Diseases
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. DIAGNOSTIC ENZYMES MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Taq Polymerase
  • 5.3. MMLV RT
  • 5.4. HIV RT
  • 5.5. UNG
  • 5.6. RNase Inhibitors
  • 5.7. Others

6. DIAGNOSTIC ENZYMES MARKET, BY PRODUCT TYPE

  • 6.1. Introduction
  • 6.2. Molecular Enzymes
  • 6.3. Clinical Enzymes

7. DIAGNOSTIC ENZYMES MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Diabetes
  • 7.3. Oncology
  • 7.4. Cardiology
  • 7.5. Infectious Diseases
  • 7.6. Others

8. DIAGNOSTIC ENZYMES MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. EKF Diagnostics
  • 10.2. Sekisui Diagnostics
  • 10.3. Negen Corporation
  • 10.4. Novozymes
  • 10.5. CustomBiotech
  • 10.6. TOYOBO
  • 10.7. Asahi Kasei
  • 10.8. Sekisui Medical Co. Ltd.
  • 10.9. NZYTech
  • 10.10. Megazyme